MedTrace Logo

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT04780984 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2021-05-10

No results posted yet for this study

Summary

A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of Three Doses of Tiotropium Bromide Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Tiotropium bromide inhalation solution

Tiotropium bromide inhalation solution

DRUG

Placebo

Placebo comparator

Sponsors & Collaborators

  • Rho, Inc.

    collaborator INDUSTRY

  • Nephron Pharmaceuticals Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-04-20
Completion
2021-04-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04780984 on ClinicalTrials.gov